Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.0067
- Book/Share 15.9713
- PB 1.5604
- Debt/Equity 0.6785
- CurrentRatio 1.2581
- ROIC 0.0897
- MktCap 141224590800.0
- FreeCF/Share 1.665
- PFCF 14.946
- PE 17.9211
- Debt/Assets 0.2946
- DivYield 0.0684
- ROE 0.0878
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, June 12, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera.
Read More
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.
Read More
4 Cheap Dividend Stocks Under $50 That Keep Raising Payouts
Published: June 12, 2025 by: 24/7 Wall Street
Sentiment: Positive
These four dividend stocks are trading below $50 and have a yield higher than 4%.
Read More
4 Battered Blue Chips Trading at Multiyear Lows Pay Huge High-Yield Dividends
Published: June 10, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Blue-chip stocks are shares of large, well-established, financially stable companies with a consistent and reliable performance history.
Read More
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YCharts 6/6/25 data on Dividends from 78, which hereafter are referred to as the Fortune Return on Leadership Dividend Dogs (FROLD). ReturnOnLeadership is based on four fundamental factors: Connection to Purpose, Strategic Clarity, Leadership Alignment, and Focused Action.
Read More
Top Cancer Stocks to Supercharge Your 2025 Portfolio
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Read More
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Published: June 10, 2025 by: Reuters
Sentiment: Neutral
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccine panel late on Monday.
Read More
Wall Street Analysts Love These Ultra-High Yield Dividend Stocks
Published: June 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
Alexandros Michailidis / iStock Editorial via Getty Images Pfizer Pharmaceutical company Pfizer Inc.
Read More
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Negative
PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.
Read More
Pfizer Inc. (PFE) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Published: June 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (NYSE:PFE ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ET Company Participants Albert Bourla - Chairman of the Board & CEO Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Asad Haider Great. Good morning, everyone, and welcome to our 46th Annual Global Healthcare Conference.
Read More
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Published: June 09, 2025 by: Benzinga
Sentiment: Positive
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Read More
Buy 7 Ideal 'Safer' May Dividends, Out Of 40 Reader Tags
Published: June 06, 2025 by: Seeking Alpha
Sentiment: Positive
My yield-based 'dogcatcher' strategy spotlights high-yield stocks whose dividends from $1,000 invested exceed their share price, favoring underdogs for income growth. Analyst targets project average net gains of 41.9% for the top ten May 2025 ReFa/Ro Dogs, with Oxford Lane Capital leading at 83.4% upside potential. All ten top ReFa/Ro Dogs currently meet my 'ideal' criteria, but caution is warranted as several have negative free cash flow margins, signaling cash-poor status.
Read More
5 Bargain Stocks With Low P/S Ratios & High Growth Return Potential
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like JAKK, GDOT, SIG, ROCK and PFE hold promise.
Read More
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
Published: June 05, 2025 by: The Motley Fool
Sentiment: Positive
It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high.
Read More
Top 3 dividend stocks to buy for 2026
Published: June 04, 2025 by: Finbold
Sentiment: Positive
Holding dividend stocks remains one of the most effective long-term strategies, with companies that pay a regular dividend often being profitable and well-positioned for future growth, even during economic downturns.
Read More
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (June 2025)
Published: June 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
Jeff J Mitchell / Getty Images News via Getty Images Pfizer (PFE) Price Prediction 2025–2030 The current consensus one-year price target for Pfizer, according to analysts, is $27.63, which represents 17.42% potential upside over the next 12 months based on PFE's current share price.
Read More
Pfizer's R&D Optimization Delivers Great Results & Secure Dividends
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Positive
PFE's meltdown has already triggered the richer forward dividend yields, made secure by the growing cash flow and the ongoing cost optimizations. The same has been observed in the FQ1'25 adj EPS outperformance, reiterated FY2025 guidance, and them "currently trending toward the upper end of the adjusted diluted EPS guidance range." While there is no avoiding the COVID-19 sales erosion and the upcoming patent cliff with ~$29B in revenues at stake, PFE has optimized its R&D efforts indeed.
Read More
Top 4 Value Stocks to Buy as Trade Tensions Still Cloud H2 Outlook
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.
Read More
Buy, Sell, Or Hold PFE Stock At $23?
Published: June 03, 2025 by: Forbes
Sentiment: Negative
Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-stage trial, and concerns about management's decisions on R&D spending and acquisitions have weighed on Pfizer's stock lately.
Read More
3 Low-Priced Dividend Stocks Paying Over 5% Right Now
Published: June 03, 2025 by: 24/7 Wall Street
Sentiment: Positive
Alexandros Michailidis / iStock Editorial via Getty Images Pfizer The years after the pandemic haven't been kind to Pfizer Inc.
Read More
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning t.
Read More
Put Cash To Work: 2 Magnificent Dividends I'm Betting On
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, robust margins, and a 32-year dividend growth streak, justifying its GARP valuation. AbbVie is rapidly replacing Humira revenue with high-growth drugs, maintains industry-leading margins, and delivers a 3.5% yield with double-digit EPS growth potential.
Read More
PFE or LLY: Which Is the Better Value Stock Right Now?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Are Investors Undervaluing Pfizer (PFE) Right Now?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
5 Valuable Price-to-Book Stocks to Strengthen Your Portfolio
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and PSFE are some such stocks.
Read More
Collaborations for Change: AUA and Pfizer Select Recipients for $1.5 Million Grant Program to Improve Advanced Prostate Cancer Care
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
BALTIMORE, May 29, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is excited to announce it has selected seven grant winners to split $1.5 million as part of a collaborative initiative with Pfizer External Research & Grants (ER&G) which is aimed to improve the quality of care for individuals with advanced prostate cancer.
Read More
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
Published: May 26, 2025 by: Seeking Alpha
Sentiment: Positive
Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics' Ivonescimab outperforming Pembrolizumab in a Phase III trial. While immature, results from competitors such as Instil Bio are promising. We think Instil Bio, through its low valuation, and Pfizer, given its dividend yield, constitute good Buy opportunities to get exposure to the field.
Read More
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
Published: May 23, 2025 by: MarketBeat
Sentiment: Positive
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. NYSE: PFE certainly catches the eye of income-seeking investors.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Dr. Albert Bourla D.V.M., Ph.D.
- Employees 81000